 | | Vol. 10.48 – 13 December, 2022 |
| |
|
|
| In this Phase III, multicenter, open-label trial, researchers randomly assigned patients with unresectable stage IIIC or IV melanoma in a 1:1 ratio to receive tumor-infiltrating lymphocytes or anti–cytotoxic T-lymphocyte antigen 4 therapy.
[New England Journal of Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators constructed a library of CARs containing ~2,300 synthetic costimulatory domains. These CARs promoted diverse cell fates, which were sensitive to motif combinations and configurations.
[Science] |
|
|
|
| Researchers developed a genetic platform that combined autonomous antigen-induced production of an accessory molecule with constitutive CAR expression in a single lentiviral vector called Uni-Vect.
[Cancer Cell] |
|
|
|
| The authors assessed safety, imaging dose and timing, pharmacokinetics, and immunogenicity of zirconium-89-labeled, CD8-specific, one-armed antibody positron emission tomography tracer 89ZED88082A in patients with solid tumors before and ~30 days after starting ICI therapy.
[Nature Medicine] |
|
|
|
| To gain insight into the process of mucosal healing, researchers longitudinally examined the immune cell composition during intestinal damage and regeneration.
[Immunity] |
|
|
|
| To determine if exogenous IL-2 in the tumor microenvironment could overcome immune checkpoint blockade resistance, investigators engineered MSCs to successfully deliver IL-2 mutein dimer to tumor-infiltrating lymphocytes.
[Nature Cell Biology] |
|
|
|
| Scientists used DNA origami nanostructures as 2D scaffolds to regulate the spatial presentation of activating ligands at nanoscale to construct high-effective artificial antigen-presenting cells.
[Science Advances] |
|
|
|
| Guided by single-cell transcriptomic profiling of human and mouse tumors, researchers devised a strategy to distinguish and separate immunostimulatory from immunosuppressive tumor monocytes by surface CD88 and Sca-1 expression.
[Cell Reports] |
|
|
|
|
| Investigators include a comprehensive analysis of the complete ecosystem of the head and neck squamous cell carcinoma tumor microenvironment, utilizing data-rich resources such as The Cancer Genome Atlas.
[Nature Reviews Cancer] |
|
|
|
| The authors summarize recent advances in our understanding of aged T cell metabolism, with a focus on the bioenergetic and immunologic features of T cell subsets unique to the aging process.
[Cell Metabolism] |
|
|
|
|
| Moderna, Inc. and Merck announced that the Phase IIb KEYNOTE-942 trial of mRNA-4157/V940, in combination with KEYTRUDA®, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of recurrence-free survival of patients with stage III/IV melanoma following complete resection.
[Moderna Inc.] |
|
|
|
|
| February 9 – 12, 2023
Cancun, Mexico |
|
|
|
|
|
| | Flanders Institute for Biotechnology – Leuven, Belgium |
|
|
|
| | The Ottawa Hospital Research Institute – Ottawa, Ontario, Canada |
|
|
|
| | VIB-UAntwerp – Antwerp, Belgium |
|
|
|
| | Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| | Case Western Reserve University – Cleveland, Ohio, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
